These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3121868)

  • 1. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
    O'Brien WM; Lynch JH
    J Urol; 1988 Jan; 139(1):66-8. PubMed ID: 3121868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer methods of hormonal therapy for prostate cancer.
    Soloway MS
    Urology; 1984 Nov; 24(5 Suppl):30-8. PubMed ID: 6437034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
    Hopkins SC; Palmieri GM; Niell HB; Moinuddin M; Soloway MS
    Cancer; 1984 Jan; 53(1):117-21. PubMed ID: 6689994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
    Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
    Mundy AR
    Br J Urol; 1979 Dec; 51(6):570-4. PubMed ID: 534843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
    Crawford ED; Allen JA
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):961-3. PubMed ID: 2126738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
    N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
    Mooppan MM; Wax SH; Kim H; Wang JC; Tobin MS
    J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of hydroxyproline excretion in patients with prostatic cancer.
    Romics I; Budavári I; Kisbenedek L; Balogh F
    Int Urol Nephrol; 1981; 13(3):275-8. PubMed ID: 7327902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
    Crawford ED; Goodman P; Blumenstein B
    Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
    [No Abstract]   [Full Text] [Related]  

  • 16. Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan.
    Johns WD; Garnick MB; Kaplan WD
    Clin Nucl Med; 1990 Jul; 15(7):485-7. PubMed ID: 2116949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone analogs and prostatic cancer.
    Swanson LJ; Seely JH; Garnick MB
    Crit Rev Oncol Hematol; 1988; 8(1):1-26. PubMed ID: 2964939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 19. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB; Jeannet C; Depierre D; Courvoisier B
    Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III studies in prostatic cancer with leuprolide acetate.
    Seely JH
    J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.